8月11日，康方生物盘中上涨3.15%，报104.7港元，成交额4320.14万港元。
消息面上，公司近日宣布其Trop2/Nectin-4双特异性ADC（AK146D1）联合依沃西单抗治疗乳腺癌的II期临床研究已完成首例患者给药，标志着IO2.0+ADC2.0融合战略持续落地。此前该药物联合依沃西治疗晚期非小细胞肺癌的II期研究亦已完成首例给药，管线布局加速拓展。同时，公司多项国际注册性研究密集推进，包括依沃西联合维恩妥尤单抗一线治疗尿路上皮癌的国际II/III期注册研究启动，为其第6项国际多中心注册研究，全球化布局持续加速。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.